Magnolia Medical Technologies
Medical Devices, 220 W Mercer St, Seattle, Washington, 98119, United States, 51-200 Employees
Phone Number: 12*********
Who is MAGNOLIA MEDICAL TECHNOLOGIES
Magnolia Medical Technologies is on a Mission to ZERO. Today, we offer healthcare institutions a solution to some of their biggest hidden problems contamination leading to misdiagnosis of...
Read More
-
Headquarters: 220 W Mercer St, Seattle, Washington, 98119, United States
-
Date Founded: 2006
-
Employees: 51-200
-
Revenue: $50 Million to $100 Million
-
Active Tech Stack: See technologies
Industry: Medical Devices
SIC Code: 3841
|
NAICS Code: 339112 |
Show More
Does something look wrong? Fix it. | View contact records from MAGNOLIA MEDICAL TECHNOLOGIES
Magnolia Medical Technologies Org Chart and Mapping
Email
Phone
Tony Dedeo
Director of Operations | Emerging Growth - Strategy and Implementation - Npi - Cogs Reductions
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Magnolia Medical Technologies
Answer: Magnolia Medical Technologies's headquarters are located at 220 W Mercer St, Seattle, Washington, 98119, United States
Answer: Magnolia Medical Technologies's phone number is 12*********
Answer: Magnolia Medical Technologies's official website is https://magnolia-medical.com
Answer: Magnolia Medical Technologies's revenue is $50 Million to $100 Million
Answer: Magnolia Medical Technologies's SIC: 3841
Answer: Magnolia Medical Technologies's NAICS: 339112
Answer: Magnolia Medical Technologies has 51-200 employees
Answer: Magnolia Medical Technologies is in Medical Devices
Answer: Magnolia Medical Technologies contact info: Phone number: 12********* Website: https://magnolia-medical.com
Answer: Magnolia Medical Technologies is on a Mission to ZERO. Today, we offer healthcare institutions a solution to some of their biggest hidden problems contamination leading to misdiagnosis of bloodstream infections, including sepsis, which can lead to unnecessary and prolonged antibiotic therapy, and false-positive CLABSIs. Tomorrow, we aspire to create a world free of in-vitro diagnostic errors where rapid, accurate test results improve the lives of patients and providers alike. We know that setting new standards of care is a journey enabled by purposeful innovation, partnerships, and perseverance. As the first step of our journey, we have successfully developed and proven our evidence-based technology platform, Steripath, which weve coupled with unparalleled support to change clinical practices and prevent unnecessary patient harm as well as system-wide costs associated with the misdiagnosis of sepsis. Our mission is further enabled by reducing false-positive CLABSIs and leveraging our extensive intellectual property portfolio consisting of over 100 issued method, apparatus, and design patents and 70+ patent applications pending to address other important sources of diagnostic error that are harmful to patients and costly to hospitals.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month